Inclusion Criteria:

- Recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic or
cytologic confirmation of the original primary tumor is required.

- Must have measurable disease which is defined as at least one lesion that can be
accurately measured in at least one dimension. Each lesion must be >20mm when
measured by conventional techniques.

- Must have at least one "target lesion" to be used to assess response.

- Platinum-sensitive tumors, defined as a platinum free interval of at least 6 months,
and may have had up to two prior treatment regimens.

- ECOG score of 0 or 1

- Life expectancy of 12 weeks or longer

- 18 years of age or older

- Adequate bone marrow, renal, neurologic and liver function

- Normal blood coagulation parameters

Exclusion Criteria:

- Chemotherapy within last 3 weeks

- Current, recent (within 4 weeks), or planned participation in an experimental drug
study other than a Genentech-sponsored bevacizumab cancer study.

- Known bleeding disorder or coagulopathy, or history of stroke.

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study entry or the anticipation of need for major surgical procedure during
the course of the study.

- Minor surgical procedures within 14 days of study entry.

- Significant cardiovascular disease, NYHA Grade II or greater congestive heart
failure, serious cardiac arrhythmia requiring medication, a history of DVT, or Grade
II or greater, clinically significant peripheral vascular disease within 1 year of
study entry.

- Urine protein:creatinine ration greater than or equal to 1.0

- History or clinical evidence of CNS disease

- Patients with other invasive malignancies, with the exception of non-melanoma skin
cancer, who have evidence of disease within last three years.

- More than 2 prior lines of chemotherapy

- Previous treatment with a VEGF targeted inhibitor or antibody

- Serious non-healing wound, ulcer or bone fracture

- Prior radiation therapy to more than one-third of hematopoietic sites.

- History of abdominal fistulas, gastrointestinal perforation, intra-abdominal abscess,
or partial bowel obstruction within 6 months

- Pregnant or lactating